PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Benserazide→

Benserazide PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
322-35-0
Molecular formula
C10H15N3O5
Molecular weight
257.24 g/mol
Drug class
Peripheral aromatic L-amino-acid (DOPA) decarboxylase inhibitor
Mechanism of action
Inhibits peripheral DOPA decarboxylase and does not appreciably enter the central nervous system. When co-administered with levodopa, it reduces peripheral conversion of levodopa to dopamine, increasing levodopa availability to the CNS and reducing the required levodopa dose. Benserazide alone has no antiparkinson activity.
Indications / reported uses
  • Used in combination with levodopa for Parkinsonism; benserazide is not an antiparkinson treatment by itself

Sources: NLM MeSH (Benserazide) · Health Canada product monograph listing for levodopa/benserazide

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Benserazide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Benserazide Permitted Daily Exposure (PDE) report (the Benserazide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Benserazide Occupational Exposure Limit (OEL) report (the Benserazide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.